MX367255B - Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). - Google Patents

Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).

Info

Publication number
MX367255B
MX367255B MX2014012619A MX2014012619A MX367255B MX 367255 B MX367255 B MX 367255B MX 2014012619 A MX2014012619 A MX 2014012619A MX 2014012619 A MX2014012619 A MX 2014012619A MX 367255 B MX367255 B MX 367255B
Authority
MX
Mexico
Prior art keywords
treatment
aminosteroids
associated disease
ptp1b
ptp1b associated
Prior art date
Application number
MX2014012619A
Other languages
English (en)
Other versions
MX2014012619A (es
Inventor
Mclane Michael
Ruiz-White Inez
Lee Maloy W
R Wolfe Henry
Original Assignee
Ohr Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohr Pharmaceutical Inc filed Critical Ohr Pharmaceutical Inc
Publication of MX2014012619A publication Critical patent/MX2014012619A/es
Publication of MX367255B publication Critical patent/MX367255B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Esta solicitud se relaciona con el uso de compuestos aminoesteroides para la inhibición selectiva de la enzima PTP1B en un mamífero para el tratamiento de diabetes.
MX2014012619A 2012-04-20 2013-04-19 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). MX367255B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636252P 2012-04-20 2012-04-20
PCT/US2013/037330 WO2013158970A2 (en) 2012-04-20 2013-04-19 Aminosteroids for the treatment of a ptp1b associated disease

Publications (2)

Publication Number Publication Date
MX2014012619A MX2014012619A (es) 2015-01-15
MX367255B true MX367255B (es) 2019-08-12

Family

ID=48325893

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014012619A MX367255B (es) 2012-04-20 2013-04-19 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b).
MX2019009539A MX2019009539A (es) 2012-04-20 2014-10-17 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009539A MX2019009539A (es) 2012-04-20 2014-10-17 Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b ( ptp1b).

Country Status (15)

Country Link
US (6) US9546194B2 (es)
EP (2) EP2838907B1 (es)
JP (4) JP6165843B2 (es)
KR (3) KR20150003798A (es)
AU (3) AU2013249111B2 (es)
CA (1) CA2870671C (es)
DK (1) DK2838907T3 (es)
ES (1) ES2736310T3 (es)
HR (1) HRP20191348T1 (es)
HU (1) HUE044769T2 (es)
MX (2) MX367255B (es)
PL (1) PL2838907T3 (es)
PT (1) PT2838907T (es)
TR (1) TR201911039T4 (es)
WO (1) WO2013158970A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2838907T (pt) * 2012-04-20 2019-08-05 Ohr Pharmaceutical Inc Aminoesteróides para o tratamento de uma doença associada a ptp1b
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
MA50094A (fr) 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
CN107802626B (zh) * 2017-10-11 2020-01-21 南昌大学 降血糖组合物及其制备方法、用途
US11406647B2 (en) * 2017-11-06 2022-08-09 Cold Spring Harbor Laboratory Method and compositions for forming a copper-containing complex and uses thereof
WO2019190950A1 (en) * 2018-03-27 2019-10-03 Enterin, Inc. Methods and compositions for treating hallucinations and conditions related to the same
EP3823977A4 (en) * 2018-07-20 2022-05-04 Cold Spring Harbor Laboratory (PYRIDINYLMETHYL) BUTANEDIAMINE DERIVATIVES WHICH CHELATE COPPER
EP4007764A4 (en) * 2019-08-02 2023-08-09 Enterin, Inc. HUMAN ENT-03 AMINOSTEROL COMPOUNDS, RELATED COMPOSITIONS COMPRISING THEM, AND METHODS OF USE THEREOF
US20220372066A1 (en) * 2019-08-02 2022-11-24 Enterin, Inc. Human squalamine derivatives (ent-06), related compositions comprising the same, and method of using the same
WO2023230593A1 (en) 2022-05-27 2023-11-30 Cold Spring Harbor Laboratory Ptp1b inhibitors for treating lung injury

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403683A (en) * 1942-04-25 1946-07-09 Relchstein Tadeus Compounds of the cyclopentanopolyhydrophenanthrene series and process of making same
US3636210A (en) * 1968-02-02 1972-01-18 Merck & Co Inc Cholanic acid and cholenic acid compositions and method of treatment
IT1255450B (it) * 1992-06-30 1995-10-31 Montefarmaco Spa Uso di acidi biliari come agenti antivirali
WO1994019366A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
CA2157594A1 (en) 1993-03-10 1994-09-15 Leah L. Frye Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
ATE259375T1 (de) 1995-06-07 2004-02-15 Genaera Corp Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
US7410959B1 (en) * 2000-07-13 2008-08-12 Genaera Corporation Therapeutic uses for aminosterol compounds
DE60028791T2 (de) 1999-09-10 2007-05-24 Novo Nordisk A/S Modulatoren der protein tyrosin phosphatase (ptpases)
AU7476800A (en) 1999-09-10 2001-04-10 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
ATE309250T1 (de) 1999-09-10 2005-11-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
EP1235849A2 (en) * 1999-12-09 2002-09-04 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
CA2508913A1 (en) * 2002-12-24 2004-07-15 The University Of British Columbia Angiogenic compounds and uses thereof
JP2006165843A (ja) * 2004-12-06 2006-06-22 Matsushita Electric Ind Co Ltd 画像処理装置
MX2008013592A (es) 2006-04-21 2009-03-06 Genaera Corp Induccion de perdida de peso e inhibicion selectiva de la proteina tirosina fosfatasa 1b.
CA2922021C (en) 2007-09-06 2018-01-09 Ohr Pharmaceutical, Inc. A method for treating diabetes
KR101260221B1 (ko) * 2011-12-01 2013-05-06 주식회사 엘지화학 마스크
PT2838907T (pt) * 2012-04-20 2019-08-05 Ohr Pharmaceutical Inc Aminoesteróides para o tratamento de uma doença associada a ptp1b

Also Published As

Publication number Publication date
JP6165843B2 (ja) 2017-07-19
AU2020203736B2 (en) 2021-12-02
JP2019059781A (ja) 2019-04-18
US20170129914A1 (en) 2017-05-11
WO2013158970A3 (en) 2013-12-12
TR201911039T4 (tr) 2019-08-21
ES2736310T3 (es) 2019-12-27
JP2021073250A (ja) 2021-05-13
EP2838907B1 (en) 2019-05-22
US20200270300A1 (en) 2020-08-27
MX2014012619A (es) 2015-01-15
KR20150003798A (ko) 2015-01-09
US11434257B2 (en) 2022-09-06
JP2017178951A (ja) 2017-10-05
AU2013249111B2 (en) 2018-08-09
AU2013249111A1 (en) 2014-11-06
JP2015514781A (ja) 2015-05-21
EP3556765B1 (en) 2022-02-23
HK1205516A1 (en) 2015-12-18
KR101963312B1 (ko) 2019-03-28
KR102057812B1 (ko) 2019-12-19
US20190202858A1 (en) 2019-07-04
AU2018256561A1 (en) 2018-11-22
CA2870671A1 (en) 2013-10-24
US20250002525A1 (en) 2025-01-02
KR20190034685A (ko) 2019-04-02
US10556923B2 (en) 2020-02-11
KR20160091435A (ko) 2016-08-02
HRP20191348T1 (hr) 2019-10-18
JP6457010B2 (ja) 2019-01-23
AU2020203736A1 (en) 2020-06-25
MX2019009539A (es) 2019-09-26
US20150099727A1 (en) 2015-04-09
PT2838907T (pt) 2019-08-05
US9546194B2 (en) 2017-01-17
PL2838907T3 (pl) 2019-12-31
DK2838907T3 (da) 2019-08-05
HUE044769T2 (hu) 2019-11-28
EP2838907A2 (en) 2015-02-25
WO2013158970A2 (en) 2013-10-24
AU2018256561B2 (en) 2020-03-05
CA2870671C (en) 2020-05-12
EP3556765A1 (en) 2019-10-23
US20230203088A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
AU2018256561A1 (en) Aminosteroids for the treatment of a PTP1B associated disease
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
IL228001A0 (en) Antibodies to 70cd
GEP201706612B (en) Methods for the treatment of breast cancer
ZA201209644B (en) Extending the number of general purpose registers available to instructions
IL229495B (en) A sigma receptor ligand for the treatment of pain resulting from type ii diabetes
AP2013007179A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
EA201390948A1 (ru) Лечение боли, обусловленной смещением базального слоя эндометрия
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
PL2632475T3 (pl) Kompozycje do leczenia wrzodów peryferyjnych o zróżnicowanym pochodzeniu
EP3015864A4 (en) Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
GB2509663A (en) Treatment of adrenal insufficiency
IL231498B (en) Compositions for the treatment of peripheral ulcers of various origins
PT2560662T (pt) Sulodexide para a utilização no tratamento de patologias nas quais as metaloproteínases estão envolvidas
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
IL234494B (en) Composition for the treatment of menopausal symptoms
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
ZA201400488B (en) Compounds for the treatment of cancers associated with human papillomavirus
FR2987092B1 (fr) Ensemble de reducteurs.
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
GB201009091D0 (en) Compounds for the treatment of clostridium difficile-associated disease
MX2013006526A (es) Dosis de los derivados de arilsulfonamida.

Legal Events

Date Code Title Description
FG Grant or registration